Familial risk of psychosis in obsessive-compulsive disorder: Impact on clinical characteristics, comorbidity and treatment response.
Clinical characteristics
Familial risk
Obsessive-compulsive
Psychosis
Treatment response
Journal
Journal of psychiatric research
ISSN: 1879-1379
Titre abrégé: J Psychiatr Res
Pays: England
ID NLM: 0376331
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
07
06
2022
revised:
12
08
2022
accepted:
03
10
2022
pubmed:
12
11
2022
medline:
15
12
2022
entrez:
11
11
2022
Statut:
ppublish
Résumé
Family studies in obsessive-compulsive disorder (OCD) indicate higher rates of psychosis among their first-degree relatives (FDRs). However, the etiological and clinical relationships between the two disorders remain unclear. We compared the clinical characteristics and pharmacological treatment response in patients diagnosed with OCD with a family history of psychosis (OCD-FHP), with a family history of OCD (OCD-FHO) and those with sporadic OCD (OCD-S). A total of 226 patients who met DSM-IV criteria for OCD (OCD-FHP = 59, OCD-FHO = 112, OCD-S = 55) were included for analysis. All patients were evaluated using the Mini International Neuropsychiatric Interview (MINI 6.0.0), Yale-Brown Obsessive-Compulsive Scale (YBOCS), and the Family Interview for Genetic Studies (FIGS). Treatment response was characterized over naturalistic follow-up. The three groups did not differ across any demographic or clinical variables other than treatment response. Patients in the OCD-FHP group were found to have received a greater number of trials with serotonin reuptake inhibitors (SRI) [F (2,223) = 7.99, p < 0.001], were more likely to have failed ≥2 trials of SRIs (χ
Sections du résumé
BACKGROUND
Family studies in obsessive-compulsive disorder (OCD) indicate higher rates of psychosis among their first-degree relatives (FDRs). However, the etiological and clinical relationships between the two disorders remain unclear. We compared the clinical characteristics and pharmacological treatment response in patients diagnosed with OCD with a family history of psychosis (OCD-FHP), with a family history of OCD (OCD-FHO) and those with sporadic OCD (OCD-S).
METHODS
A total of 226 patients who met DSM-IV criteria for OCD (OCD-FHP = 59, OCD-FHO = 112, OCD-S = 55) were included for analysis. All patients were evaluated using the Mini International Neuropsychiatric Interview (MINI 6.0.0), Yale-Brown Obsessive-Compulsive Scale (YBOCS), and the Family Interview for Genetic Studies (FIGS). Treatment response was characterized over naturalistic follow-up.
RESULTS
The three groups did not differ across any demographic or clinical variables other than treatment response. Patients in the OCD-FHP group were found to have received a greater number of trials with serotonin reuptake inhibitors (SRI) [F (2,223) = 7.99, p < 0.001], were more likely to have failed ≥2 trials of SRIs (χ
Identifiants
pubmed: 36368245
pii: S0022-3956(22)00544-1
doi: 10.1016/j.jpsychires.2022.10.001
pmc: PMC7615106
mid: EMS185463
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
557-563Subventions
Organisme : DBT-Wellcome Trust India Alliance
ID : IA/CPHI/20/1/505266
Pays : India
Investigateurs
Naren P Rao
(NP)
Palanimuthu T Sivakumar
(PT)
Arun Kandasamy
(A)
Urvakhsh Meherwan Mehta
(UM)
Bharath Holla
(B)
Jayant Mahadevan
(J)
Shyam Sundar Arumugham
(SS)
Sydney Moirangthem
(S)
K G Vijay Kumar
(KGV)
Jagadisha Thirthalli
(J)
Muralidharan Kesavan
(M)
Janardhanan C Narayanaswamy
(JC)
Mathew Varghese
(M)
Pratima Murthy
(P)
Bangalore N Gangadhar
(BN)
Meera Purushottam
(M)
Bhupesh Mehta
(B)
Thennarasu Kandavel
(T)
Bhaskarpillai Binukumar
(B)
Jitender Saini
(J)
Odity Mukherjee
(O)
Mitradas M Panicker
(MM)
Upinder S Bhalla
(US)
Sumantra Chattarji
(S)
Padinjat Raghu
(P)
Mahendra Rao
(M)
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None of the authors have any competing interests to declare with respect to the work presented within this manuscript.
Références
Schizophr Res. 2015 Apr;163(1-3):17-23
pubmed: 25432636
Science. 2018 Jun 22;360(6395):
pubmed: 29930110
Psychiatry Res. 2008 May 30;159(1-2):254-8
pubmed: 18378321
Compr Psychiatry. 2003 Jul-Aug;44(4):311-6
pubmed: 12923709
J Affect Disord. 1985 Jul;9(1):13-8
pubmed: 3160743
Psychiatry Res. 2015 Jul 30;228(1):112-20
pubmed: 25957648
Am J Psychiatry. 1991 May;148(5):612-6
pubmed: 2018162
Schizophr Res. 2014 Feb;152(2-3):458-68
pubmed: 24361303
JAMA Psychiatry. 2014 Nov;71(11):1215-21
pubmed: 25188738
Compr Psychiatry. 2015 Jan;56:141-8
pubmed: 25308405
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):327-37
pubmed: 16412548
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:233-9
pubmed: 23410525
Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):31-6
pubmed: 15635656
Compr Psychiatry. 2012 Aug;53(6):775-82
pubmed: 22136738
Mol Psychiatry. 2014 Feb;19(2):209-13
pubmed: 24126925
Arch Gen Psychiatry. 1989 Nov;46(11):1006-11
pubmed: 2684084
Psychiatry Res. 2021 Feb;296:113647
pubmed: 33429328
CNS Spectr. 2008 Aug;13(8):705-11
pubmed: 18704026
Psychiatry Res. 2012 Dec 30;200(2-3):554-9
pubmed: 22503329
Mol Psychiatry. 2019 Mar;24(3):409-420
pubmed: 29317742
Compr Psychiatry. 2014 Oct;55(7):1520-5
pubmed: 25088515
Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):13-9
pubmed: 15635694
Front Psychiatry. 2019 Jun 17;10:386
pubmed: 31263430
Compr Psychiatry. 2008 May-Jun;49(3):262-8
pubmed: 18396185
Acta Psychiatr Scand. 2011 Feb;123(2):136-46
pubmed: 20880068
Aust N Z J Psychiatry. 2014 Sep;48(9):852-60
pubmed: 24740253
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1009-12
pubmed: 19447155
Arch Gen Psychiatry. 1989 Nov;46(11):1012-6
pubmed: 2510699
J Am Acad Child Adolesc Psychiatry. 2014 Dec;53(12):1308-16
pubmed: 25457929
Biol Psychiatry Glob Open Sci. 2022 Apr;2(2):115-126
pubmed: 35712048
Mol Psychiatry. 2016 Feb;21(2):270-6
pubmed: 25824302
Schizophr Res. 2019 Jul;209:58-63
pubmed: 31133461
Am J Psychiatry. 2022 Mar;179(3):216-225
pubmed: 34789012
Schizophr Bull. 2015 Sep;41(5):1076-83
pubmed: 25512596
J Affect Disord. 2004 May;80(1):19-28
pubmed: 15094254
Psychol Med. 2023 Jan;53(2):371-378
pubmed: 33926592
BMC Psychiatry. 2018 Apr 18;18(1):106
pubmed: 29669557